Company news: Dendreon and CPPIB Credit Investments

Share this article:

Dendreon agreed to sell its royalty interest in Victrelis (boceprevir) for $125 million in cash, the company said. The firm did not disclose the exact royalty rate. The royalty interest was acquired by CPPIB Credit Investments, a wholly-owned subsidiary of CPP Investment Board, and the transaction is expected to close this month. ISI Group analyst Mark Schoenebaum estimated peak global Victrelis sales of $970.5 million in 2014. All-oral therapies, such as Gilead/Pharmassset's PSI-7977 could reach market in 2015 and are expected to impact currently marketed HCV drugs like Merck/Roche's Victrelis.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.